Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
SEATTLE, March 14, 2017 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will be presented in a poster session at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington D.C., April 1-5, 2017.
Based on Aptevo’s proprietary ADAPTIR™ protein therapeutic platform, the Company’s latest bispecific candidates targeting CD123 were designed to redirect T-cell cytotoxicity to CD123-expressing tumors cells, a cell surface receptor highly expressed in several hematological malignancies. Results being presented at AACR will examine the in vitro and in vivo activity of optimized lead candidates, APVO436 and APVO437, in preclinical models of acute myeloid leukemia (AML).
| Title: | Bispecific anti-CD123 x anti-CD3 ADAPTIR Molecules for Redirected T-cell Cytotoxicity in Hematological Malignancies |
| Date/Time: | April 2, 2017 – 1:00 – 5:00 pm ET |
| Session Title: | T-Cell Immunity to Cancer – New Progress (Immunology) |
| Abstract ID: | 597/1 |
Abstracts for the AACR annual meeting are available and can be viewed online at www.aacr.org. Aptevo’s poster presentation will be available on the Investor Relations section of the Company’s website at www.aptevotherapeutics.com following the poster session.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Source: Aptevo Therapeutics Stacey Jurchison Senior Director, Investor Relations and Corporate Communications 206-859-6628 [email protected]
